Osimertinib (Tagrisso) has been TGA registered as adjuvant therapy after tumour resection in early stage, EGFR-mutated non-small cell lung cancer (NSCLC). It is the first targeted therapy available to prevent recurrence of disease in this patient group. The evidence comes from the international ADAURA trial, which included Australian sites and investigators. The RCT, published in ...
First targeted therapy approved to prevent recurrence of early stage NSCLC
By Mardi Chapman
7 Jun 2021